Start a new manuscript submission or continue a submission in progress
Go to submission siteEditorial board
EDITORIAL BOARD
EDITOR-IN-CHIEF
Dr. Luis G. Valerio Jr, U.S. Food and Drug Administration (FDA), Washington, DC, USA
Luis G. Valerio, Jr., Ph.D., is currently an Associate Director at the U.S. Food and Drug Administration (FDA). Dr. Valerio has a strong background in public health and is multi-faceted having served with increasing responsibilities at the FDA Center for Drug Evaluation and Research, Center for Food Safety and Applied Nutrition, and the Center for Tobacco Products; contributing in areas of review, risk/safety science, compliance and enforcement, and applied regulatory research. For over 10 years he has made significant contributions to the field of computational toxicology, providing foundations and creating pioneering in silico predictive models for expert decision-support. Prior to joining the FDA, he was Head of Toxicology and Translational Science at Verto Solutions, LLC, in Washington, DC. Of notable significance, he was Scientific Director of the Flavor and Extract Manufacturers Association (FEMA) of the United States. At FEMA he ensured the safety of flavors for the industry. He has also been an industrial consumer product safety toxicologist for several years. He received his Ph.D. in Pharmaceutical Science (1998) from the University of Colorado, and was a Gastroenterology Fellow at the University of Colorado School of Medicine where he focused on hepatic metabolism of xenobiotics and molecular mechanisms of toxicity. He was a U.S. National Science Foundation International Research Postdoctoral Fellow at the Autonomous University of Barcelona, Spain where he studied the biochemistry of the alcohol dehydrogenase enzyme family. He received his Bachelor of Arts in Environmental, Population, and Organismic Biology from the University of Colorado, at Boulder. Valerio is internationally recognized and has strong experience in emerging and predictive technologies in toxicology, pharmacokinetics, regulatory toxicology, and in pharmaceutical product science. His research interests include predictive metabolism, computational modeling, and development of strategies and methods for risk analysis. He has been on the advisory board of Expert Opinion on Drug Metabolism and Toxicology since 2009 and has been Editor-in-Chief since 2011.
Editorial Board Members
Prof. Karel Allegaert, KU Leuven, Leuven, Belgium
Prof. Mark Cronin, Liverpool John Moores University, Liverpool, UK
Prof. Jose De Leon, University of Kentucky, Lexington, KY, USA
Prof. Amílcar Falcão, University of Coimbra, Coimbra, Portugal
Prof. Simone Ferrero, University of Genoa, Genoa, Italy
Prof. Gert Fricker, University of Heidelberg, Heidelberg, Germany
Prof. Slobodan Jankovic, University of Kragujevac, Kragujevac, Serbia
Prof. Jeffrey Lipman, University of Queensland, Brisbane, Australia
Dr. Geert Mannens, Janssen Pharmaceuticals, Beerse, Belgium
Prof. Olavi Pelkonen, University of Oulu, Oulu, Finland
Dr. Mario Pellegatti, Retired GSK Director, Verona, Italy
Prof. Godefridus J Peters, VU University Medical Center, Amsterdam, Netherlands
Dr. Italo Poggesi, Certara, Lombardia, Italy
Dr. Adrian Ray, Gilead Sciences Inc., Foster City, CA, USA
Prof. Jim Riviere, Kansas State University, Manhattan, KS, USA
Prof. André Scheen, University of Liège, Liège, Belgium
Prof. Nicolas Simon, Aix-Marseille Université, Marseille, France
Prof. Edoardo Spina, University of Messina, Messina, Italy
Prof. Yoshiya Tanaka, University of Occupational & Environmental Health Japan, Kitakyushu, Japan
Prof. Rolf Teschke, Klinikum Hanau, Hanau, Germany
Prof. Brian Tomlinson, Chinese University of Hong Kong, Hong Kong SAR
Prof. Jack Uetrecht, University of Toronto, Toronto, ON, Canada
Prof. Vasilis Vasiliou, Yale University, New Haven, CT, USA
Prof. Thomas J Walsh, Cornell University, Ithaca, NY, USA
Dr. Hong Wan, WHDeX Consulting AB, Mölndal, Sweden
Prof. Baojian Wu, Jinan University, Guangzhou, China